• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [24124 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     National Institute for Health and Care Excellence (NICE) Ozanimod for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 828
2021     National Institute for Health and Care Excellence (NICE) Ozanimod for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 706
2005     Health Technology Assessment Section, Ministry of Health Malaysia (MaHTAS) Ozone therapy
2005     Malaysian Health Technology Assessment Unit (MHTAU) Ozone therapy
2005     Institute for Clinical Effectiveness and Health Policy (IECS) Ozone therapy for the management of lumbar disc pathologies
2005     Andalusian Health Technology Assessment Area (AETSA) Ozonotherapy in the treatment of fibromialgia - non-systematic review
2012     HAYES, Inc. P-Stim (Biegler GmbH) auricular electroacupuncture for pain management
2011     HAYES, Inc. P-Stim (Biegler GmbH) auricular electroacupuncture for pain management
2015     NIHR Horizon Scanning Centre (NIHR HSC) P1vital® eHealth Emotional Test Battery (eH-ETB) for early detection of treatment effect in depression
2003     The Swedish Council on Health Technology Assessment (SBU) Pacemaker resynchronization of ventricular rhythm (CRT) in chronic heart failure - early assessment briefs (Alert)
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice cemiplimab (Libtayo®) for the treatment of non-small cell lung carcinoma (NSCLC)
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice dabrafenib/trametinib (Tafinlar®/Mekinist®)
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice esketamine nasal spray (Spravato®) for the treatment of adults with treatment-resistant major depressive disorder
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice for the lock procedure drug betibeglogene autotemcel (Zynteglo®)
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice ipilimumab (Yervoy®) in combination with nivolumab (Opdivo®)
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice isatuximab (Sarclisa®) for the treatment of multiple myeloma
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice multiple myeloma
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice niraparib (Zejula®)
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice on avelumab (Bavencio®) for treating urothelial cell carcinoma
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice on entrectinib (Rozlytrek®) for the treatment of ROS1 fusion-positive advanced non-small cell lung cancer
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice onasemnogene abeparvovec (Zolgensma®) for the treatment of SMA
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice pertuzumab and trastuzumab (Phesgo®) for the treatment of breast cancer
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice polatuzumab vedotin (Polivy®) in combination with bendamustine and rituximab (Pola-BR) for the treatment of r/r DLBCL
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice ravulizumab (Ultomiris®) for the treatment of PNH and aHUS
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice venetoclax (Venclyxto®)
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice venetoclax (Venclyxto®) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)
1999     University HealthSystem Consortium (UHC) Paclitaxel
2011     NIHR Horizon Scanning Centre (NIHR HSC) Paclitaxel (Paclical) for epithelial ovarian cancer, fallopian tube cancer or peritoneal cancer – second or third line
2011     NIHR Horizon Scanning Centre (NIHR HSC) Paclitaxel (Paclical) for epithelial ovarian cancer, fallopian tube cancer or peritoneal cancer – second or third line
2007     HAYES, Inc. Paclitaxel (Taxol) for adjuvant and neoadjuvant treatment of breast cancer
2008     HAYES, Inc. Paclitaxel (Taxol) for adjuvant and neoadjuvant treatment of non-small cell lung cancer
2007     HAYES, Inc. Paclitaxel (Taxol) for treatment of metastatic breast cancer
2010     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Paclitaxel albumin (Abraxane®)
2014     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Paclitaxel albumin-bound nanoparticles (Abraxane®)
1996     Wessex Institute for Health Research and Development (WIHRD) Paclitaxel as a first line chemotherapy agent in the treatment of ovarian cancer
2004     NIHR Horizon Scanning Centre (NIHR HSC) Paclitaxel as adjuvant therapy in early stage breast cancer - horizon scanning review
2015     National Institute for Health and Care Excellence (NICE) Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 362
2017     National Institute for Health and Care Excellence (NICE) Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer. NICE technology appraisal guidance 476
2015     Health Quality Ontario (HQO) Paclitaxel drug-eluting stents in peripheral arterial disease: a health technology assessment
2015     Health Quality Ontario (HQO) Paclitaxel drug-eluting stents in peripheral arterial disease: OHTAC recommendation
2006     Quality Improvement Scotland (NHS QIS ) Paclitaxel for the adjuvant treatment of early node-positive breast cancer
2014     NIHR Horizon Scanning Centre (NIHR HSC) Paclitaxel poliglumex (Xyotax) for advanced ovarian cancer – maintenance therapy
2013     NIHR Horizon Scanning Centre (NIHR HSC) Paclitaxel polyglutamate (Opaxio) in combination with temozolamide and radiotherapy for glioblastoma – first line
2021     NIHR Health Technology Assessment programme Paclitaxel-assisted balloon angioplasty of venous stenosis in haemodialysis access: PAVE RCT
2003     Adelaide Health Technology Assessment (AHTA) Paclitaxel-eluting coronary stents to improve coronary artery function and prevent restenosis, following coronary angioplasty
2010     HAYES, Inc. Paclitaxel-eluting stents for treatment of coronary artery disease
2005     Quality Improvement Scotland (NHS QIS ) Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer
2014     NIHR Horizon Scanning Centre (NIHR HSC) Pacritinib for myelofibrosis
2015     NIHR Horizon Scanning Centre (NIHR HSC) Padeliporfin (Tookad soluble) for localised prostate cancer – first line
2018     National Institute for Health and Care Excellence (NICE) Padeliporfin for untreated localised prostate cancer. NICE technology appraisal guidance 546
2020     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Paediatric cardiac surgery - literature review
2019     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Paediatric deep brain stimulation
2007     Medical Services Advisory Committee (MSAC) Paediatric liver transplantation
2023     Agency for Care Effectiveness (ACE) Paige Prostate Detect to assist the diagnosis of prostate cancer
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Pain management for pediatric patients in the emergency department: guidelines
2015     Agency for Healthcare Research and Quality (AHRQ) Pain management injection therapies for low back pain
2011     Agency for Healthcare Research and Quality (AHRQ) Pain management interventions for hip fracture
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Pain neurophysiology education for the management of persistent pain: clinical evidence and guidelines
2001     Israel Center for Technology Assessment in Health Care (ICTAHC) Pain relief in major trauma patients: An Israeli perspective
2010     Canadian Agency for Drugs and Technologies in Health (CADTH) Pain scales in acute care settings: a review of the accuracy and reliability
2014     HAYES, Inc. PALB2-associated hereditary breast cancer
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Palbociclib (Ibrance®) in combination with fulvestrant for the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer
2021     Swiss Federal Office of Public Health (FOPH) Palbociclib (Ibrance®), ribociclib (Kisqali®) and abemaciclib (Verzenios®) for the treatment of hormone receptor (HR)-positive, human epidermal growth factor (HER2)-negative advanced breast cancer
2014     NIHR Horizon Scanning Centre (NIHR HSC) Palbociclib for advanced ER-positive/HER2-negative breast cancer in post-menopausal women – first line in combination with letrozole
2015     NIHR Horizon Scanning Centre (NIHR HSC) Palbociclib for advanced or metastatic, oestrogen-receptor positive, HER2-negative, recurrent breast cancer – second line
2016     NIHR Health Technology Assessment programme Palbociclib for treating metastatic, hormone receptor-positive, HER2-negative breast cancer [ID915]
2022     National Institute for Health and Care Excellence (NICE) Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. NICE technology appraisal guidance 836
2022     National Institute for Health and Care Excellence (NICE) Palforzia for treating peanut allergy in children and young people. NICE technology appraisal guidance 769
2005     University HealthSystem Consortium (UHC) Palifermin
2012     NIHR Horizon Scanning Centre (NIHR HSC) Palifosfamide tromethamine (Zymafos) for advanced soft tissue sarcoma – first line
2011     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Paliperidone palmitate (Xeplion®)
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Paliperidone palmitate (Xeplion®) 50 mg, 75 mg, 100 mg and 150 mg prolonged release suspension for injection
2000     University HealthSystem Consortium (UHC) Palivizumab
2003     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Palivizumab (Synagis)
2014     HAYES, Inc. Palivizumab (Synagis) prophylaxis for respiratory syncytial virus infection in preterm infants
2012     HAYES, Inc. Palivizumab (Synagis®) prophylaxis for respiratory syncytial virus infection in preterm infants
2011     NIHR Health Technology Assessment programme Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses
2023     Agency for Care Effectiveness (ACE) Palivizumab for preventing serious lower respiratory tract disease caused by respiratory syncytial virus
2007     Canadian Agency for Drugs and Technologies in Health (CADTH) Palivizumab prophylaxis against respiratory syncytial virus
2007     Institute for Clinical Effectiveness and Health Policy (IECS) Palivizumab to prevent respiratory syncytial virus infections of the lower tract
2005     Norwegian Knowledge Centre for the Health Services (NOKC) Palliation of cancer pain
2005     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Palliation of inoperable oesophageal carcinoma - primary research
2014     Medical Services Advisory Committee (MSAC) Palliative care consultation items
2018     Penn Medicine Center for Evidence-based Practice (CEP) Palliative care in the outpatient setting for patients with heart failure or advanced lung disease
2021     Penn Medicine Center for Evidence-based Practice (CEP) Palliative care screening tools
2003     Health Council of the Netherlands Gezondheidsraad (GR) Palliative chemotherapy. Review. Expert consultation
2007     National Institute for Health and Care Excellence (NICE) Palliative photodynamic therapy for advanced oesophageal cancer. NICE interventional procedures guidance 206
2021     NIHR Health Technology Assessment programme Palliative radiotherapy combined with stent insertion to reduce recurrent dysphagia in oesophageal cancer patients: the ROCS RCT
1996     Wessex Institute for Health Research and Development (WIHRD) Pallidotomy for Parkinson's disease
2005     HAYES, Inc. Pallidotomy for treatment of Parkinson's disease
2002     The Swedish Council on Health Technology Assessment (SBU) Pallidotomy in Parkinson's disease - early assessment briefs (ALERT)
1999     Wessex Institute for Health Research and Development (WIHRD) Pallidotomy, thalamotomy and deep brain stimulation for severe Parkinson's disease
2015     NIHR Health Technology Assessment programme Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation
2006     Institute for Clinical Effectiveness and Health Policy (IECS) Pancreas islet stem cells and transplant for the treatment of diabetes mellitus
2015     Health Quality Ontario (HQO) Pancreas islet transplantation for patients with type 1 diabetes mellitus: a clinical evidence review
2015     Health Quality Ontario (HQO) Pancreas islet transplantation for patients with type 1 diabetes mellitus: OHTAC recommendation
2002     Blue Cross Blue Shield Association (BCBS) Pancreas retransplantation
2003     Institute for Clinical Systems Improvement (ICSI) Pancreas transplant for insulin-dependent diabetes
1996     Australian Health Technology Advisory Committee (AHTAC) Pancreas transplantation
2006     HAYES, Inc. Pancreas transplantation alone (PTA)